These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32620644)

  • 1. Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
    Jeong JY; Park TI; Ahn D
    Anticancer Res; 2020 Jul; 40(7):4001-4010. PubMed ID: 32620644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
    Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
    Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
    Hong AM; Ferguson P; Dodds T; Jones D; Li M; Yang J; Scolyer RA
    Oral Oncol; 2019 May; 92():33-39. PubMed ID: 31010620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking.
    Lilja-Fischer JK; Eriksen JG; Georgsen JB; Vo TT; Larsen SR; Cheng J; Busch-Sørensen M; Aurora-Garg D; Steiniche T; Overgaard J
    Acta Oncol; 2020 Jun; 59(6):666-672. PubMed ID: 32079442
    [No Abstract]   [Full Text] [Related]  

  • 7. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
    Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
    Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and characterisation of prognostically significant PD-L1
    Young RJ; Bressel M; Porceddu S; Cernelc J; Savas P; Liu H; Urban D; Thai AA; Cooper C; Fua T; Neeson P; Rischin D; Solomon B
    Oral Oncol; 2020 Feb; 101():104516. PubMed ID: 31838340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
    Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
    Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T Cells and PD-L1 Expression as Prognostic Indicators in a Low Prevalence of HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Atipas K; Laokulrath N; Petsuksiri J; Ratanaprasert N; Pongsapich W
    Curr Oncol; 2023 Jan; 30(2):1450-1460. PubMed ID: 36826072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
    Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI
    Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of PD-L1
    Solomon B; Young RJ; Bressel M; Urban D; Hendry S; Thai A; Angel C; Haddad A; Kowanetz M; Fua T; Corry J; Fox S; Rischin D
    Cancer Immunol Res; 2018 Mar; 6(3):295-304. PubMed ID: 29378694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
    Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H
    J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma.
    Anjos RSD; Carvalho MV; Costa RTF; Vasconcelos BCDE; Moraes SLD; Pellizzer EP
    Braz Oral Res; 2024; 38():e095. PubMed ID: 39356903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
    Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW
    Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.